News

MassDevice4d
Novocure wins CE mark for its lung cancer treatment wearable
The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.
Summit Therapeutics Rallies After Lung Cancer Drug Shows Positive Results
Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...
Mirage News10d
Lung Cancer In Blood
To diagnose lung cancer and determine the optimal treatment strategy, physicians typically rely on tissue examination. However, taking biopsies is ...
‘Access to cancer care matters’: Physicians discuss advancements in cancer care and technology
Four physicians spoke on the panel, which was held at the Basketball Hall of Fame in Springfield, to discuss advancements in ...
Business Wire4d
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
“There are few treatment options for people living with this ... “The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s ...
Non-Small Cell Lung Cancer Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...
PhillyVoice9d
Prostate cancer therapy being tested at Main Line Health may 'open up the door' to new treatments for advanced cancers
The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...